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nsulin receptor substrates (IRS-1 and IRS-2) are essential
for intracellular signaling by insulin and insulin-like
growth factor-I (IGF-I), anabolic regulators of bone meta-
 
bolism.  Although mice lacking the 
 
IRS-2
 
 gene (
 
IRS-2
 
 
 
/
 
 
 
mice) developed normally, they exhibited osteopenia with
decreased bone formation and increased bone resorption.
 
Cultured 
 
IRS-2
 
 
 
/
 
 
 
 osteoblasts showed reduced differentiation
and matrix synthesis compared with wild-type osteo-
blasts. However, they showed increased receptor activator
of nuclear factor 
 
 
 
B ligand (RANKL) expression and osteo-
clastogenesis in the coculture with bone marrow cells,
which were restored by reintroduction of IRS-2 using an
adenovirus vector. Although IRS-2 was expressed and
I
 
phosphorylated by insulin and IGF-I in both osteoblasts
and osteoclastic cells, cultures in the absence of osteo-
blasts revealed that intrinsic IRS-2 signaling in osteoclastic
cells was not important for their differentiation, function,
or survival. It is concluded that IRS-2 deﬁciency in osteo-
blasts causes osteopenia through impaired anabolic function
and enhanced supporting ability of osteoclastogenesis. We
propose that IRS-2 is needed to maintain the predominance
of bone formation over bone resorption, whereas IRS-1
maintains bone turnover, as we previously reported; the
integration of these two signalings causes a potent bone
anabolic action by insulin and IGF-I.
 
Introduction
 
Bone is continually being remodelled according to physio-
logical circumstances through bone formation by osteoblasts
and resorption by osteoclasts. These two processes are closely
coupled, and bone mass is maintained without change by
their balance in healthy adults. A rupture of the balance
causing a predominance of bone resorption over bone for-
mation results in bone loss such as that seen in osteoporosis.
Among many systemic and local factors involved in the
regulation of bone metabolism, insulin and insulin-like
growth factor-I (IGF-I)* are known to play important anabolic
roles (Canalis, 1993; Thomas et al., 1997). Patients with insulin
deficiency as exemplified by type 1 diabetes are associated
with osteoporosis (Krakauer et al., 1997; Piepkorn et al.,
1997); those with Laron syndrome caused by IGF-I deficiency
also exhibit this condition (Laron et al., 1999). A reduction
in IGF-I is also implicated as an important factor in the etiology
of involutional osteoporosis, especially of age-related bone loss
(Nicolas et al., 1994; Rosen, 1994; Reed et al., 1995; Canalis,
1997). However, the cellular and molecular mechanism under-
lying bone loss due to the deficiency of insulin and IGF-I
signalings has not yet been clarified.
Insulin and IGF-I initiate cellular responses by binding to
distinct cell surface receptor tyrosine kinases that regulate
a variety of signaling pathways controlling metabolism,
growth, and survival. Insulin receptor substrates (IRSs) are
essential substrates of both of the receptor tyrosine kinases,
which integrate the pleiotropic effects of insulin, IGF-I, and
other cytokines on cellular function (Kadowaki et al., 1996;
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White, 1998; Burks and White, 2001). The mammalian
IRS family contains at least four members, ubiquitous IRS-1
and IRS-2, adipose tissue-predominant IRS-3 (Lavan et al.,
1997b), and IRS-4, which is expressed in thymus, brain, and
kidney (Lavan et al., 1997a). In bone cells, IRS-1 and IRS-2
are expressed, and we previously reported that IRS-1 in os-
teoblasts is indispensable for maintaining bone turnover be-
cause 
 
IRS-1
 
 
 
/
 
 
 
 mice showed osteopenia with a low bone
turnover in which both bone formation and resorption were
decreased (Ogata et al., 2000).
IRS-1 and IRS-2 signalings are reported to have distinct
biological roles and to be differentially expressed in a variety
of cells. Regarding glucose homeostasis, IRS-1 plays an im-
portant role in the metabolic actions of insulin and IGF-I
mainly in skeletal muscle and adipose tissue, whereas IRS-2
does so in the liver (Yamauchi et al., 1996; Bruning et al.,
1997). Most hemopoietic cells express IRS-2 but not IRS-1
(Sun et al., 1997), and in bone cells as well, IRS-1 expres-
sion was limited to osteoblastic cells, whereas IRS-2 was ex-
pressed in both osteoblastic and osteoclastic cells (Ogata et
al., 2000). In addition, IRS-2 is known as a signaling mole-
cule of interleukin (IL)-4 and IL-13, cytokines with inhibi-
tory effects on osteoclastogenesis (Wang et al., 1998; Scopes
et al., 2001; Wurster et al., 2002). Hence, there is a possibil-
 
ity that IRS-2 has a different function in the regulation of
bone metabolism from that of IRS-1, especially in the cata-
bolic phase by osteoclastic cells.
This study analyzed the bones of mice lacking the 
 
IRS-2
 
gene (
 
IRS-2
 
 
 
/
 
 
 
 mice), which we generated by homologous
recombination (Kubota et al., 2000). 
 
IRS-2
 
 
 
/
 
 
 
 mice were
normal in appearance with a body size similar to wild-type
(WT) mice and showed no abnormalities in major organs
such as brain, heart, liver, spleen, or kidney, except that their
general adiposity was slightly increased and females were in-
fertile (Withers et al., 1998; Burks et al., 2000; Kubota et
al., 2000; Tobe et al., 2001). These phenotypes were also
different from 
 
IRS-1
 
 
 
/
 
 
 
 mice whose growth was significantly
retarded and in which group both males and females were
fertile (Araki et al., 1994; Tamemoto et al., 1994). Further-
more, 
 
IRS-2
 
 
 
/
 
 
 
 mice displayed type 2 diabetes with periph-
eral insulin resistance and pancreatic 
 
 
 
 cell dysfunction
characterized by reduction in 
 
 
 
 cell mass, whereas 
 
IRS-1
 
 
 
/
 
 
 
mice did not develop diabetes due to an enhanced 
 
 
 
 cell
mass that compensated for the peripheral insulin resistance.
In this study, we first found osteopenia in 
 
IRS-2
 
 
 
/
 
 
 
 mice,
and sought to determine the cellular and molecular mecha-
nism underlying the abnormality of bone metabolism using in
vivo morphological analyses and in vitro cell culture systems.
Figure 1. IRS-2
 /  mice showed osteopenia both 
in trabecular and cortex bones. (A) Plain X-ray 
images of femora and tibiae (left) and three-
dimensional CT images of distal femora (right) 
of representative WT and IRS-2
 /  littermates 
(8 wk old). (B) BMD of the femora and tibiae of WT 
and IRS-2
 /  littermates. (B, left) BMD of the whole 
femora and tibiae at 4, 8, 12, and 16 wk of age. *, 
significantly different from WT mice; P   0.05. 
(B, right) BMD of each of 20 equal longitudinal 
divisions of the femora and tibiae of 8-wk-
old mice. Data are expressed as means
(symbols)   SEMs (error bars) for 12 bones/group 
for WT and IRS-2
 /  mice. 
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Results
 
IRS-2
 
 
 
/
 
 
 
 mice showed osteopenia with an uncoupling 
of decreased bone formation and increased 
bone resorption
 
Because the lengths of femora and tibiae did not differ be-
tween WT and 
 
IRS-2
 
 
 
/
 
 
 
 littermates at 8 wk of age (Fig. 1
A), IRS-2 was suggested not to be involved in the regulation
of skeletal growth. However, 
 
IRS-2
 
 
 
/
 
 
 
 mice showed osteope-
nia in these long bones by X-ray and three-dimensional CT
analyses (Fig. 1 A). This was also found in vertebral bodies
(unpublished data). Bone mineral density (BMD) of these
bones was decreased by 
 
 
 
10–15% in 
 
IRS-2
 
 
 
/
 
 
 
 mice at 4, 8,
12, and 16 wk of age compared with their WT littermates
(Fig. 1 B, left). To determine the distribution of BMD of
long bones at 8 wk, the femora and tibiae were analyzed by
dividing them longitudinally into 20 equal regions (Fig. 1 B,
right). BMD of each fraction was similarly decreased in all
fractions of 
 
IRS-2
 
 
 
/
 
 
 
 bones, suggesting that both trabecular
and cortex bones were similarly affected by IRS-2 deficiency.
Histological features of the proximal tibiae of 8-wk-old
 
IRS-2
 
 
 
/
 
 
 
 mice displayed a decrease in the trabecular bone
volume (Fig. 2 A, left). Calcein double labeling showed that
the width between the two stained labels was narrower in
 
IRS-2
 
 
 
/
 
 
 
 (Fig. 2 A, middle); however, the number of tar-
trate-resistant acid phosphatase (TRAP)–positive osteoclasts
was higher in 
 
IRS-2
 
 
 
/
 
 
 
 than in WT littermates (Fig. 2 A, right).
Histomorphometric measurements revealed that bone volume
(BV/TV) was 
 
 
 
30% decreased, and parameters for bone re-
sorption (Oc.N/B.Pm, Oc.S/BS, and ES/BS) were 70–80% in-
creased in 
 
IRS-2
 
 
 
/
 
 
 
 compared with WT littermates (Table I).
Regarding bone formation parameters, osteoblast number
(Ob.S/BS) was slightly, although not significantly, increased in
 
IRS-2
 
 
 
/
 
 
 
 
 
bones. However, mineral apposition rate (MAR), re-
flecting the ability of an individual osteoblast to form bone, was
 
 
 
50% decreased, and, consequently, bone formation rate
(BFR/BS) was significantly lower in 
 
IRS-2
 
 
 
/
 
 
 
 compared with
WT littermates. Taking these in vivo observations together,
 
IRS-2
 
 
 
/
 
 
 
 mice exhibited osteopenia with increased osteoclastic
bone resorption and decreased osteoblastic bone formation,
suggesting that the two actions were not coupled. The thickness
of the growth plate at the proximal tibiae was not different be-
tween 
 
IRS-2
 
 
 
/
 
 
 
 and WT littermates (70.8 
 
 
 
 8.9 and 76.9 
 
 
 
10.8 
 
 
 
m, mean 
 
 
 
 SEM of eight mice each, respectively), indi-
cating that IRS-2 signaling is not important for chondrocytes.
To further investigate the regulation of expression of
genes related to bone metabolism by IRS-2 deficiency, we
compared mRNA levels of matrix proteins and key mole-
cules for osteoblast and osteoclast differentiations in long
bones between 
 
IRS-2
 
 
 
/
 
 
 
 and WT littermates (Fig. 2 B). Ex-
pression of matrix proteins such as type I collagen, alkaline
phosphatase (ALP), osteocalcin, and osteopontin was de-
creased in 
 
IRS-2
 
 
 
/
 
 
 
 bones, which was consistent with the
histomorphometric data showing reduced bone formation.
However, expression of the putative central determinants of
major pathways for osteoblast differentiation, i.e., Runx2
(Karsenty, 2001), LDL receptor–related protein 5 (Lrp5)
(Patel and Karsenty, 2002), and inhibitor of differentia-
tion-1 (Id-1) (Ogata et al., 1993), was not different between
Figure 2. IRS-2
 /  bone showed an uncoupling of decreased bone formation and increased bone resorption in vivo. (A) Histological features at 
proximal tibiae of WT and IRS-2
 /  littermates (8 wk old). In Villanueva-Goldner staining (left), mineralized bone is stained green and unmineralized 
osteoid red. Bar, 50  m. In calcein double labeling (middle), mineralization front is stained as a green line. Bar, 10  m. In TRAP staining, 
TRAP-positive osteoclasts are stained red. Bar, 50  m. Data of histomorphometric parameters are shown in Table I. (B) Expression of matrix 
proteins (type I collagen, ALP, osteocalcin, and osteopontin) and key molecules for differentiations of osteoblasts (Runx2, Lrp5, and Id-1) and 
osteoclasts (RANKL, osteoprotegerin, and MMP-13) in long bones of WT and IRS-2
 /  littermates (5 wk old) by semiquantitative RT-PCR. 
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WT and 
 
IRS-2
 
 
 
/
 
 
 
 bones, implying an independent signaling
pathway of IRS-2 in osteoblasts. Positive regulatory mole-
cules of bone resorption, such as receptor activator of nu-
clear factor 
 
 
 
B ligand (RANKL) (Suda et al., 1999) and ma-
trix metalloproteinase-13 (MMP-13) (Uchida et al., 2000),
were increased in 
 
IRS-2
 
 
 
/
 
 
 
 bones, which was also consistent
with the histomorphometric data showing enhanced bone
resorption. The stimulation of expression of osteoproteg-
erin, a decoy receptor of RANKL and a negative regulator of
osteoclastic bone resorption, observed in 
 
IRS-2
 
 
 
/
 
 
 
 bones
might possibly be due to a compensative response to en-
hanced bone resorption, as is reported in postmenopausal
women (Yano et al., 1999).
The serum insulin level was significantly higher in 
 
IRS-2
 
 
 
/
 
 
 
mice than in WT littermates both before (0.91 
 
 
 
 0.08 vs.
0.25 
 
 
 
 0.06 ng/ml at 8 wk and 1.23 
 
  0.16 vs. 0.44  
0.07 ng/ml at 16 wk, mean   SEM of five mice each) and
after (1.64   0.09 vs. 0.54   0.04 ng/ml at 8 wk and 2.33  
0.39 vs. 0.67   0.12 ng/ml at 16 wk) glucose load, as re-
ported previously (Kubota et al., 2000). Serum IGF-I level
was similar between IRS-2
 /  and WT littermates (134.21  
11.42 vs. 132.14   10.65 ng/ml, respectively) at 8 wk, with
no significant change at 16 wk in either type of mice.
IRS-2 was expressed and phosphorylated in both 
osteoblasts and osteoclastic cells of WT mice
Because IRS-1 and IRS-2 are reported to be differentially ex-
pressed in a variety of cells and tissues having different bio-
logical roles, we compared their expression patterns in pri-
mary calvarial osteoblasts. Macrophage colony-stimulating
factor (M-CSF)–dependent bone marrow macrophages
(M-BMM ) as osteoclast precursors and mature osteoclasts
isolated from the coculture of osteoblasts and bone marrow
cells were taken from WT and IRS-2
 /  littermates. Both
IRS-1 and IRS-2 were expressed in WT osteoblasts, whereas
in IRS-2
 /  osteoblasts, only IRS-1 was expressed with no
compensatory increase for IRS-2 deficiency (Fig. 3 A). Re-
Table I. Histomorphometry of trabecular and cortex bones of tibiae
Trabecular Cortex
BV/TV Ob.S/BS MAR BFR Oc.N/B.Pm Oc.S/BS ES/BS C.Th
%%  m/d mm
3/cm
2/y /100 mm % %  10
 1 mm
WT 9.86   0.74 8.93   1.83 2.03   0.25 4.06   0.44 136.19   19.26 4.92   0.68 5.22   0.89 2.59   0.13
IRS-2
 /  6.95   0.63
b 13.71   2.51 1.08   0.16
b 2.71   0.38
a 244.27   22.96
b 8.71   1.03
b 9.14   0.91
b 2.18   0.12
a
Parameters for the trabecular bone were measured in an area 1.2 mm in length from 0.5 mm below the growth plate at the proximal metaphysis of the tibiae
in Villanueva-Goldner and calcein double-labeled sections. Parameters for the cortex bone were measured at the midpoint of the tibiae. Data are expressed
as means   SEMs for eight bones/group for WT and IRS-2
 /  mice. BV/TV, trabecular bone volume expressed as a percentage of total tissue volume; Ob.S/
BS, percentage of bone surface covered by cuboidal osteoblasts; MAR, mineral apposition rate; BFR, bone formation rate expressed by MAR   percentage
of bone surface exhibiting double labels plus one half single labels; Oc.N/B.Pm, number of mature osteoclasts in 10 cm of bone perimeter; Oc.S/BS,
percentage of bone surface covered by mature osteoclasts; ES/BS, percentage of eroded surface; C.Th, cortex thickness.
aSignificantly different from WT mice; P   0.05.
bSignificantly different from WT mice; P   0.01.
Figure 3. IRS-2 was expressed and phosphorylated in both osteoblasts and 
osteoclastic cells of WT mice. (A) Expression of IRS-1 and IRS-2 in osteoblasts, 
preosteoclastic M-BMM , and mature osteoclasts from WT and IRS-2
 /  littermates 
was determined by semiquantitative RT-PCR. Total RNA was extracted from 
cultured osteoblasts from neonatal calvariae, M-BMM  in the presence of soluble 
RANKL and M-CSF, osteoclasts formed in the coculture of marrow cells, and osteoblasts. IRS-1 expression was not seen in osteoclastic cells 
even when the amount of template cDNA or the number of amplification cycles was increased. (B) Immunohistochemical stainings with an 
anti–IRS-2 antibody ( -IRS-2, left) and a nonimmune serum as a control (right) in the proximal tibial metaphysis of 4-wk-old WT mice. Positive 
and specific stainings shown in brown are seen in both osteoblasts on the bone surface and osteoclasts (arrowheads). GP, growth plate. Bar, 
50  m. (C) Phosphorylation of IRS-2 in osteoblasts and M-BMM  from WT and IRS-2
 /  mice in the control culture and cultures stimulated 
by insulin or IGF-I. Osteoblasts and M-BMM  from WT and IRS-2
 /  littermates were cultured with and without insulin or IGF-I for 2 min, 
and extracted cellular proteins were immunoprecipitated with an anti–IRS-2 antibody ( -IRS-2). After being subjected to SDS-PAGE, they 
were immunoblotted with an antiphosphotyrosine antibody ( -pTyr).Role of insulin receptor substrate-2 in osteoblasts | Akune et al. 151
garding cells of osteoclastic lineage, IRS-1 expression was
not detected either in M-BMM  or mature osteoclasts, and
only IRS-2 was expressed in both of these cells from WT
mice (Fig. 3 A).
Immunohistochemical analysis confirmed the expression
pattern of IRS-2 in the proximal tibial metaphysis of 4-wk-
old WT mice (Fig. 3 B). It was localized in both osteoblasts
and osteoclasts on the bone surface. This staining was spe-
cific to IRS-2 because neither of these cells was stained with
a nonimmune serum.
Fig. 3 C shows the immunoblotting with an antiphos-
photyrosine antibody for the extracts immunoprecipitated
with an anti–IRS-2 antibody in cultured osteoblasts and
M-BMM . IRS-2 protein was confirmed to be expressed in
both cells from WT mice, but not in those from IRS-2
 / 
mice. This protein was phosphorylated by insulin and IGF-I
potently in osteoblasts whereas slightly in M-BMM .
Differentiation and anabolic function of osteoblasts 
were impaired by IRS-2 deficiency
To learn the cellular mechanism underlying the abnormali-
ties in the bone of IRS-2
 /  mice, we first compared the pro-
liferation, differentiation, and matrix synthesis of cultured
osteoblasts from WT and IRS-2
 /  calvariae. Cell prolifera-
tion determined by [
3H]thymidine uptake was similarly seen
between WT and IRS-2
 /  cultures (Fig. 4 A); however, cell
differentiation determined by ALP activity was significantly
decreased in IRS-2
 /  not only in the control culture, but
also in the culture with insulin or IGF-I (Fig. 4 B). Neither
potent stimulation of cell proliferation by FGF-2 nor that
of cell differentiation by bone morphogenetic protein 2
(BMP-2) was decreased by IRS-2 deficiency. Alizarin red S
staining also showed decreased calcified matrix synthesis by
IRS-2
 /  osteoblasts in cultures with and without insulin/
IGF-I (Fig. 4 C). Here again, similar potent stimulation by
BMP-2 was seen in WT and IRS-2
 /  osteoblast cultures,
suggesting that IRS-2 and BMP-2 systems are independent
in osteoblasts. These results indicate that osteoblast differen-
tiation and anabolic function, but not its proliferation, were
impaired by IRS-2 deficiency.
We further compared the mRNA levels of Runx2, Lrp5,
and Id-1, in addition to the matrix proteins type I collagen,
ALP, osteocalcin, and osteopontin in cultured osteoblasts
(Fig. 4 D). The results were similar to those seen in vivo:
matrix proteins were decreased, but none of Runx2, Lrp5,
and Id-1 was affected by IRS-2 deficiency. This again indi-
cates that IRS-2 does not directly impact these major path-
ways for osteoblast differentiation.
Osteoclastogenesis and RANKL expression in 
osteoblasts were enhanced by IRS-2 deficiency
Osteoclasts are known to be derived from hemopoietic cells
and to require the cell–cell interaction with osteoblasts/stro-
mal cells for differentiation. To investigate osteoclast forma-
tion, we measured the number of TRAP-positive multi-
nucleated osteoclasts formed in the coculture system of
osteoblasts and bone marrow cells. Osteoclastogenesis in the
coculture induced by the bone resorptive factors prostaglan-
din E2 (PGE2), IL-11, and 1,25(OH)2D3 was more in-
creased when both cells were derived from IRS-2
 /  mice
than when both cells were derived from WT mice (Fig. 5 A,
top). IGF-I slightly, but not significantly, induced osteoclas-
togenesis in both WT and IRS-2
 /  cocultures. IL-4 and IL-
13 inhibited 1,25(OH)2D3-induced osteoclastogenesis in
the WT coculture. Although IRS-2 is known as a signaling
molecule of IL-4 and IL-13, neither of the inhibitory actions
was different between WT and IRS-2
 /  cocultures. These
results indicate that IRS-2 signaling acts inhibitorily on
the induction of osteoclastogenesis by PGE2, IL-11, and
1,25(OH)2D3, but is not related to its inhibition by IL-4 or
IL-13. The results were reproducible when spleen cells were
used instead of bone marrow cells as a source of hemopoietic
cells (unpublished data). Because RANKL is known to be a
key membrane-associated molecule expressed on osteoblasts/
stromal cells inducing osteoclastogenesis (Suda et al., 1999),
we examined the regulation of RANKL expression in osteo-
blasts from WT and IRS-2
 /  mice by these factors (Fig. 5
A, bottom). The regulation of RANKL expression showed
Figure 4. Osteoblast differentiation and matrix synthesis, but not 
proliferation, were impaired by IRS-2 deficiency. (A) Proliferation 
determined by [
3H]TdR incorporation into osteoblasts from WT and 
IRS-2
 /  calvariae cultured with and without insulin, IGF-I, or FGF-2 
for 24 h. (B) ALP activity of osteoblasts from WT or IRS-2
 /  calvariae 
cultured with and without insulin, IGF-I, or BMP-2 for 14 d. For A 
and B, data are expressed as means (bars)   SEMs (error bars) for 
eight wells/group. *, significant decrease by IRS-2 deficiency; 
P   0.05. (C) Calcified matrix synthesis determined by Alizarin red 
S staining of osteoblasts from WT or IRS-2
 /  calvariae cultured 
with and without insulin, IGF-I, or BMP-2 for 21 d. (D) Expression of 
Runx2, Lrp5, Id-1, type I collagen, ALP, osteocalcin, and osteopontin 
in cultured osteoblasts by semiquantitative RT-PCR.152 The Journal of Cell Biology | Volume 159, Number 1, 2002
good correlation with that of osteoclastogenesis: RANKL in-
duction by the resorptive factors was increased in IRS-2
 / 
osteoblasts compared with WT osteoblasts, whereas the in-
hibition by IL-4 and IL-13 was identical in both osteoblasts.
In the presence of 1,25(OH)2D3, enhanced osteoclasto-
genesis in the coculture of IRS-2
 /  osteoblasts and IRS-2
 / 
marrow cells (IRS-2
 / :IRS-2
 / ) was normalized by replac-
ing IRS-2
 /  osteoblasts with WT osteoblasts (WT:IRS-2
 / ),
but not by replacing IRS-2
 /  marrow cells with WT mar-
row cells (IRS-2
 / :WT) (Fig. 5 B, top). When the cocul-
ture was further performed on a dentine slice for 2 d, the
area of resorption pits was correlated with the number of os-
teoclasts formed, indicating no difference of bone resorptive
function between individual WT and IRS-2
 /  osteoclasts
(Fig. 5 B, bottom). These results indicate that the increase in
bone resorption in IRS-2
 /  mice is caused by the abnormal-
ity of osteoblasts to support osteoclastogenesis by inducing
RANKL, but is not due to abnormalities of osteoclast pro-
genitors or osteoclast function.
To further investigate the association between IRS-2 defi-
ciency and the upregulation of osteoclastogenesis/RANKL
expression, we examined their restoration by reintroduction
of IRS-2 in IRS-2
 /  osteoblasts using an adenovirus vector.
When IRS-2
 /  osteoblasts infected with an adenovirus vec-
tor carrying the IRS-2 gene (AxIRS2) were cocultured with
WT marrow cells in the presence of 1,25(OH)2D3, osteo-
clastogenesis was decreased in a dose-dependent manner
based on the AxIRS2 multiplicity of infection (MOI) and
on the IRS-2 protein level determined by Western blotting,
whereas the control adenovirus vector carrying the LacZ
gene (AxLacZ) did not affect it (Fig. 5 C). Enhanced
RANKL expression in cultured IRS-2
 /  osteoblasts deter-
mined by Northern blotting was also decreased by AxIRS2
infection, but not by AxLacZ (Fig. 5 D). These results were
reproducible in the stimulation of other bone resorptive fac-
tors, PGE2 and IL-11 (unpublished data). It was therefore
confirmed that the IRS-2 signaling pathway acts inhibitorily
on enhanced osteoclastogenesis and RANKL expression in
osteoblasts by these resorptive factors.
To confirm the role of IRS-2 intrinsic to osteoclastic cells,
we investigated the differentiation and survival of osteoclasts
using the M-BMM  culture system without supporting
cells such as osteoblasts/stromal cells. Osteoclastogenesis
from cultured M-BMM  in the presence of soluble
RANKL for 3 d was similar between WT and IRS-2
 /  cul-
tures (674   71 and 641   83 cells/well, mean   SEM of
Figure 5. Osteoclastogenesis was increased 
through the upregulation of RANKL expression in 
osteoblasts by IRS-2 deficiency. (A) The number of 
TRAP-positive multinucleated osteoclasts formed 
in the coculture of osteoblasts and bone marrow 
cells from WT or IRS-2
 /  littermates was counted 
after 6 d of culture with and without IGF-I, PGE2, 
IL-11, 1,25(OH)2D3 (VD3), IL-4, or IL-13. Data are 
expressed as means (bars)   SEMs (error bars) for 
eight wells/group. *, significantly different from 
WT cultures; P   0.01 (top). Messenger RNA levels 
of RANKL in cultured WT and IRS-2
 /  osteoblasts 
were determined by Northern blot analysis after 24 h 
of culture with and without the factors above 
(bottom). (B) The number of osteoclasts formed in 
the coculture of osteoblasts and bone marrow cells 
from WT and IRS-2
 /  littermates in the presence 
of 1,25(OH)2D3 (10 nM) (top) and the pit area 
resorbed by osteoclasts for an additional 48 h of 
the coculture on a dentine slice (bottom). Data are 
expressed as means (bars)   SEMs (error bars) for 
12 wells/group. *, significantly different from WT:
WT culture; P   0.01. (C) Restoration of osteoclasto-
genesis by reintroduction of IRS-2 in IRS-2
 /  
osteoblasts using an adenovirus vector carrying 
IRS-2 gene (AxIRS2). IRS-2
 /  osteoblasts infected 
with AxIRS2 or the control AxLacZ at indicated 
MOIs were cocultured with WT marrow cells in 
the presence of 1,25(OH)2D3 for 6 d, and the number 
of TRAP-positive osteoclasts was counted (top). 
Data are expressed as means (symbols)   SEMs 
(error bars) for eight wells/group. *, significantly 
different from AxLacZ-infected cultures; P   0.01. 
IRS-2 protein level in IRS-2
 /  cultured osteoblasts 
was determined by Western blotting after 2 d of 
infection of AxLacZ or AxIRS2 (bottom). (D) RANKL 
expression by introduction of IRS-2 in WT and 
IRS-2
 /  osteoblasts. Osteoblasts infected with 
AxIRS2 or AxLacZ at 10 MOI were cultured in the 
presence of 1,25(OH)2D3 for 24 h. RANKL mRNA 
level was determined by Northern blotting.Role of insulin receptor substrate-2 in osteoblasts | Akune et al. 153
12 wells, respectively). In addition, the survival of mature
osteoclasts isolated from the M-BMM  culture did not dif-
fer between WT and IRS-2
 /  osteoclasts (the average half
life of 12 wells was 6.4 and 5.7 h, respectively). Hence, it
was concluded that intrinsic IRS-2 signaling is not impor-
tant for osteoclast function.
Discussion
In vivo morphological analyses in this study demonstrated
that  IRS-2
 /  mice exhibited osteopenia with decreased
bone formation and increased bone resorption. In vitro cell
culture analyses revealed that IRS-2
 /  osteoblasts showed
reduced ability of their differentiation and matrix synthesis.
The increased osteoclastogenesis was due to the upregulation
of RANKL in osteoblasts by IRS-2 deficiency. Although
IRS-2, but not IRS-1, was expressed and phosphorylated by
insulin/IGF-I in osteoclastic cells, intrinsic IRS-2 signaling
in these cells was not important for their differentiation,
function, or survival.
The present study revealed the difference in the physiolog-
ical roles of IRS-1 and IRS-2 in bone metabolism. IRS-2
 / 
mice exhibited an uncoupling state with decreased bone for-
mation and increased bone resorption, whereas our previous
study found that IRS-1
 /  mice displayed a decrease in both
bone formation and bone resorption, indicating a low turn-
over osteopenia (Ogata et al., 2000). Hence, IRS-1 and IRS-2
seem to have opposite effects on osteoclastogenesis and
RANKL expression in osteoblasts. The signaling specificity
through the two IRSs may be accomplished by distinct
phosphorylation patterns during interaction with various ac-
tivated receptors (Sun et al., 1997). For example, phosphati-
dylinositol 3 (PI3) kinase activities in muscle and liver cells
have functional differences in the ability of the two IRSs
(Kadowaki et al., 1996; Burks and White, 2001). In this
study, effects of bone resorptive factors, i.e., PGE2, IL-11, or
1,25(OH)2D3, on osteoclastogenesis and RANKL expres-
sion were shown to be partly inhibited by IRS-2 signaling,
suggesting some convergence of signaling pathways between
these factors and IRS-2. Because the main signaling path-
ways downstream of IRS-2 are known to be those of PI3 ki-
nase and MAPK (Kadowaki et al., 1996; Withers et al.,
1998; Burks and White, 2001), either pathway could con-
ceivably be connected with the signaling of these resorptive
factors. In fact, signalings of PGE2 and IL-11 through their
specific prostaglandin E and gp130 receptors, respectively,
are known to utilize both PI3 kinase and MAPK (Fukada et
al., 1999; Breyer et al., 2001). 1,25(OH)2D3 signaling is also
reported to be inhibited by MAPK pathway by the phosphor-
ylation of retinoid X receptor  , the heterodimer of the nu-
clear vitamin D receptor, in human keratinocytes (Solomon
et al., 1999). However, our preliminary study on the mecha-
nism of RANKL induction failed to show the involvement
of PI3 kinase, p42/44 MAPK, and p38 MAPK pathways be-
cause none of their inhibitors, LY294002, PD98059, or
SB203580, altered the upregulation of the RANKL mRNA
level by IRS-2 deficiency in cultured osteoblasts (unpub-
lished data). We therefore speculate that signaling(s) other
than PI3 kinase and these MAPKs may be involved in the
suppression of RANKL expression and osteoclastogenesis by
IRS-2. The next task ahead of us will be to elucidate the dif-
ference of signaling through IRS-1 and IRS-2 in osteoblasts.
IGF-I is a potent autocrine/paracrine factor for osteoblast
proliferation and differentiation (Canalis, 1993). A relation-
ship between bone density and IGF-I is suggested by a study
showing a correlation of serum and skeletal IGF-I levels with
bone density between two healthy inbred strains of mice
(Rosen et al., 1997). In humans, accumulating evidence has
suggested a positive correlation between the serum IGF-I
level and bone density in postmenopausal women (Nicolas et
al., 1994; Rosen, 1994; Reed et al., 1995; Canalis, 1997).
The anabolic effect of insulin on bone formation may be pri-
marily related to its ability to stimulate cell proliferation
(Thomas et al., 1997). Streptozotocin-induced diabetic ani-
mals with impaired pancreatic insulin production lose bone
rapidly, and this loss is offset by insulin replacement (Hough
et al., 1981). Clinically, type 1 diabetes with insulin defi-
ciency is associated with decreased bone mass; however, the
change of bone mass in type 2 diabetic patients is controver-
sial. Although previous reports demonstrated a decrease in
bone mass in these latter patients, accumulating evidence has
revealed that obese type 2 diabetic patients have normal or
even increased bone mass (Kao et al., 1993; van Daele et al.,
1995; Krakauer et al., 1997; Piepkorn et al., 1997). This
might be due to the increased physical stress on the skeleton,
or hyperinsulinemia seen in the earlier stage of type 2 diabe-
tes. In fact, we previously demonstrated that patients with
hyperinsulinemia are associated with the increased ossifica-
tion of the spinal ligaments (Akune et al., 2001). Whether or
not the response of bone cells to insulin is affected similarly
to that of cells responsible for glucose metabolism, such as
muscle, liver, and adipose tissue, in type 2 diabetic patients is
an important point to be elucidated. Although the IRS-2
 / 
mice develop type 2 diabetes characterized by defects in both
insulin action and insulin secretion, clinical studies on ge-
netic polymorphisms have so far failed to show a pathogenic
contribution of IRS-2 to the development of this condition
(Sesti et al., 2001; Wang et al., 2001). Hence, we do not re-
gard the IRS-2
 /  mice as a model to define mechanisms of
abnormalities of bone metabolism by type 2 diabetes. The
mice may speak for themselves as a rare model showing an
uncoupling state between bone formation and resorption.
In the histomorphometric analysis, osteoblast function
was shown to be decreased by IRS-2 deficiency; however,
the number of osteoblasts (Ob.S/BS) was either not affected
or was increased (Table I). We speculate that this increase
may be secondary to the upregulation of osteoclastic bone
resorption through the coupling mechanism between osteo-
clasts and osteoblasts. In fact, in the osteoblast culture sys-
tem in which osteoclastic cells were absent, cell proliferation
was not different between WT and IRS-2
 /  (Fig. 4 A),
whereas cell differentiation and matrix synthesis were de-
creased in the IRS-2
 /  culture. Hence, IRS-2 in osteoblasts
seems to be related to the signaling of their differentiation
and function, but not to their mitogenic or anti-apoptotic
signaling directly.
The decrease in anabolic function of IRS-2
 /  osteoblasts
was seen not only in the culture with insulin or IGF-I but
also in the control culture (Fig. 4, B, C, and D). This may
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IGF-I acting as an autocrine/paracrine factor in the culture.
The concentrations of IGF-I in the culture medium were
0.39   0.12 and 0.48   0.10 nM (mean   SEM) in the
control cultures of WT and IRS-2
 /  osteoblasts, respec-
tively. In addition, serum IGF-I levels were similar between
WT and IRS-2
 /  mice in the age from 8 to 16 wk, suggest-
ing the absence of systemic compensation for impaired
IGF-I bioactivity. Hence, the decreased bone formation in
vivo in IRS-2
 /  mice may be at least in part due to the defi-
cit of anabolic signaling of endogenous IGF-I produced by
osteoblasts acting as an autocrine/paracrine factor.
Intrinsic IRS-2 in osteoclastic cells was proven not to be
important for their differentiation, function, or survival de-
spite the fact that IRS-2 and receptors of IGF-I and insulin
are expressed in these cells (Fiorelli et al., 1996; Hou et al.,
1997; Thomas et al., 1998). Whether or not IGF-I or insulin
directly acts on osteoclastic cells is controversial (Mochizuki
et al., 1992; Hill et al., 1995), and we, in fact, failed to show
the direct action of IGF-I or insulin in the culture of
M-BMM  in the absence of osteoblasts/stromal cells (un-
published data). Furthermore, IRS-1 and IRS-2 are reported
to regulate cell apoptosis through phosphorylation of Bcl-2 in
a myeloma cell line (Ueno et al., 2000), however, these pro-
teins did not affect osteoclast survival in our previous and
present studies (Ogata et al., 2000). Hence, IGF-I/insulin
and IRS signalings are likely to regulate bone resorption more
predominantly by their indirect actions through osteoblasts/
stromal cells than by their direct actions on osteoclastic cells.
Clinically, loss of anabolic actions of insulin and IGF-I on
bone metabolism is implied to cause various bone metabolic
diseases. Taken together with our previous study, we hereby
propose that these anabolic actions are maintained as an in-
tegration of two proteins that have distinct biological roles
in osteoblasts, IRS-1 and IRS-2. The former is essential to
maintain bone turnover by upregulating anabolic function
and RANKL expression, whereas the latter is needed to re-
tain the predominance of the anabolic function over the cat-
abolic function. Distinct regulation of these two IRS pro-
teins in osteoblasts may play a key role in controlling bone
metabolism and maintaining bone homeostasis.
Materials and methods
Animals
In each experiment, homozygous WT and IRS-2
 /  mice that were litter-
mates generated from the intercross between heterozygous mice were com-
pared. All experiments were performed on male mice unless otherwise de-
scribed. All experiments were performed according to the protocol approved
by the Animal Care and Use Committee of the University of Tokyo.
Analysis of skeletal morphology
Bone radiograph was taken with a soft X-ray apparatus (SOFTEX; CMB-2).
Three-dimensional CT scan was taken using a composite X-ray analyzing
system (NX-HCP; NS-ELEX Inc.). BMD was measured by single energy
X-ray absorptiometry using a bone mineral analyzer (DCS-600R; Aloka Co.).
All histological analyses were performed using 8-wk-old WT and IRS-2
 / 
littermates. For Villanueva-Goldner staining, tibiae were fixed with etha-
nol, embedded in methyl methacrylate, and sectioned in 6- m slices. For
double labeling, mice were injected subcutaneously with 8 mg/kg body
weight of calcein at 10 and 3 d before sacrifice. TRAP-positive cells were
stained at pH 5.0 in the presence of L( )-tartaric acid using naphthol AS-
MX phosphate (Sigma-Aldrich) in N,N-dimethyl formamide as the sub-
strate. The specimens were subjected to histomorphometric analyses using
an image analyzer (System Supply Co.). Parameters for the trabecular bone
were measured in an area 1.2 mm in length from 0.5 mm below the
growth plate at the proximal metaphysis of the tibiae. Parameters for the
cortex bone were measured at the midshaft of the tibiae. The thickness of
the growth plate was measured at the proximal tibiae.
Immunohistochemistry
After perfusion of 4-wk-old WT mice with 4% buffered paraformaldehyde,
tibiae were removed and immersed in the same fixative for paraffin sec-
tions. 3-mm-thick paraffin sections were treated with 0.3% hydrogen per-
oxide in PBS. After blocking with 1% albumin in PBS, they were incubated
with a rabbit polyclonal anti–mouse IRS-2 antibody (Upstate Biotechnol-
ogy) at a dilution of 1:50 for 24 h at 4 C. The sections were incubated with
HRP-conjugated goat antibodies against rabbit IgG (Dakopatts) for 1 h at
room temperature. After washing with PBS, they were immersed in a di-
aminobenzidine solution for 10 min at room temperature to observe any
immunoreactivity. As a control, we used a rabbit nonimmune serum (Up-
state Biotechnology) of the same dilution instead of the primary antibody.
In vitro osteoblast cultures
Osteoblasts were isolated from calvariae of neonatal WT and IRS-2
 /  lit-
termates. Calvariae were digested for 10 min at 37 C in an enzyme solu-
tion containing 0.1% collagenase and 0.2% dispase five times. Cells iso-
lated by the last four digestions were combined as an osteoblast
population and cultured in  MEM containing 10% FBS. For cell prolifera-
tion assay, primary osteoblasts were inoculated at a density of 1   10
4
cells/well in a 24-multiwell plate, cultured in the same medium for 48 h,
and deprived of serum for 12 h before adding the experimental medium
with and without IGF-I (10 nM), insulin (100 nM), or FGF-2 (1 nM). Incor-
poration of [
3H]thymidine (1  Ci/ml in the medium) added for the final 3 h
was measured after 24 h of culture. For ALP activity measurement, primary
osteoblasts were inoculated at a density of 1   10
4 cells/well in a 24-mul-
tiwell plate and cultured in  MEM containing 10% FBS and 50  g/ml
ascorbic acid with and without IGF-I (10 nM), insulin (100 nM), or BMP-2
(30 ng/ml). At 14 d of culture, cells were sonicated in 10 mM Tris-HCl
buffer (pH 8.0) containing 1 mM MgCl2 and 0.5% Triton X-100. ALP activ-
ity in the lysate was measured using a Wako ALP kit (Wako Pure Chemical
Industry, Ltd.). The protein content was determined using BCA protein as-
say reagent (Pierce Chemical Co.). For Alizarin red S staining, osteoblasts
were inoculated at a density of 5   10
4 cells/well in a six-multiwell plate
in  MEM containing 10% FBS and 50  g/ml ascorbic acid and 10 mM
 -glycerophosphate. At day 21 after confluency, cultured cells were fixed
in 10% buffered formalin and stained for 10 min with 2% Alizarin red S
(pH 4.0) (Sigma-Aldrich).
Coculture of osteoblasts and bone marrow cells
Bone marrow cells were collected from long bones of 8-wk-old WT or IRS-
2
 /  littermates. TRAP-positive multinucleated osteoclasts were generated
by coculturing osteoblasts (1   10
4 cells/well) and bone marrow cells (5  
10
5 cells/well) derived from either WT or IRS-2
 /  littermates in a 24-multi-
well plate in  MEM containing 10% FBS for 6 d with and without IGF-I (10
nM), 1,25(OH)2D3 (10 nM), PGE2 (100 nM), IL-11 (10 ng/ml), IL-4 (100 ng/
ml), or IL-13 (100 ng/ml). Cells positively stained for TRAP containing more
than three nuclei were counted as osteoclasts. To determine bone resorp-
tion activity, osteoclasts formed by the coculture on 0.24% collagen gel
coated on 100-mm dishes were digested with 0.2% collagenase solution,
and a 1/50 aliquot including osteoclasts was seeded on a dentine slice. Af-
ter 48 h of culture in  MEM containing 10% FBS, the total area of pits
stained with 0.5% toluidine blue was evaluated using an image analyzer.
M-BMM  culture
We used the M-BMM  culture system as described previously (Kobayashi
et al., 2000). In brief, bone marrow cells from WT or IRS-2
 /  mice were
seeded at a density of 3   10
5 cells/well in a 24-multiwell plate and cul-
tured in  MEM containing 10% FBS with M-CSF (100 ng/ml). After cultur-
ing for 3 d, adherent cells (M-BMM ) were further cultured with M-CSF
(100 ng/ml) and soluble RANKL (100 ng/ml) for 3 d. TRAP-positive osteo-
clasts were counted. To determine the survival, osteoclasts generated as
above were deprived of M-CSF/soluble RANKL and cultured for an addi-
tional 48 h. At 3, 6, 12, 24, and 48 h, the number of TRAP-positive and try-
pan blue–negative osteoclasts was counted.
Generation of adenoviruses and gene transfer
The recombinant adenovirus vector carrying IRS-2 gene containing CAG
(cytomegalovirus immediate early enhancer   chicken actin promoter  
rabbit globin poly A signal) promoter was constructed using the Adenovi-Role of insulin receptor substrate-2 in osteoblasts | Akune et al. 155
rus Expression Vector Kit (Takara Shuzo Co., Ltd.) following the manufac-
turer’s protocol. The adenovirus vector carrying the  -galactosidase gene
(AxLacZ) was provided by Dr. I. Saito (University of Tokyo). IRS-2
 /  os-
teoblasts were seeded at a density of 1   10
4 cells/well in a 24-multiwell
plate and treated with viral suspensions for 1 h at 37 C at a concentration
indicated as the MOI for 2 d. Infection efficiency was confirmed by  -galac-
tosidase assay using X-gal as a substrate, and Western blot analysis of IRS-2.
IRS-2 protein level was also confirmed by Western blotting. For the experi-
ment of osteoclastogenesis, they were then washed three times with PBS,
and WT bone marrow cells were added at a density of 5   10
5 cells/well
with and without 1,25(OH)2D3 (10 nM), PGE2 (100 nM), or IL-11 (10 ng/
ml) and cocultured for 6 d. The number of TRAP-positive osteoclasts was
counted. For the experiment of RANKL expression, osteoblasts infected
with 10 MOI of AxIRS2 or AxLacZ were further cultured with and without
the resorptive factors above for 24 h, and the mRNA level was determined
by Northern blotting.
Immunoprecipitation and Western blot analysis
After stimulation by IGF-I (10 nM) or insulin (100 nM), cultured cells were
lysed with TNE buffer (10 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1 mM
EDTA, 10 mM NaF, 2 mM Na3VO4, 1 mM aminoethyl-benzenesulfonyl flu-
oride, and 10  g/ml aprotinin). Immunoprecipitation was performed us-
ing antibodies either noncovalently bound or conjugated to protein
G–Sepharose (GIBCO BRL). Equivalent amounts (20  g) of cell lysate were
immunoprecipitated with a polyclonal anti–mouse IRS-2 antibody (Upstate
Biotechnology) for 4 h at 4 C. Each cell lysate or immunoprecipitated pro-
tein containing an equivalent amount of protein was electrophoresed by 8%
SDS-PAGE and transferred to nitrocellulose membrane. After blocking with
5% albumin solution, they were incubated with an antiphosphotyrosine an-
tibody (Upstate Biotechnology). Immunoreactive bands were stained using
the ECL chemiluminescence reaction (Amersham Biosciences).
Northern blotting and semiquantitative RT-PCR
For Northern blot analysis, osteoblasts were cultured in  MEM containing
10% FBS with and without IGF-I (10 nM), 1,25(OH)2D3 (10 nM), PGE2 (100
nM), IL-11 (10 ng/ml), IL-4 (100 ng/ml), or IL-13 (100 ng/ml). Total RNA was
extracted using an ISOGEN kit (Wako Pure Chemical). 30  g of total RNA
was electrophoresed in 1.2% agarose–formaldehyde gels and transferred
onto nylon membrane filters (Hybond-N; Amersham Biosciences). The
membranes were hybridized for 12 h at 42 C with cDNA probes for mouse
RANKL, which were labeled using a multirandom primer oligonucleotide la-
beling kit (Boehringer) and [
32P]dCTP. Semiquantitative RT-PCR was per-
formed within an exponential phase of the amplification. Total mRNA (1  g)
was reverse transcribed using Super Script reverse transcriptase (Takara
Shuzo Co., Ltd.) with random hexamer (Takara Shuzo Co., Ltd.), and 5% of
the reaction mixture was amplified with LA-Taq DNA polymerase (Takara
Shuzo Co., Ltd.) using the following primer pairs: 5 -GCAGCCCCACCTGC-
CTCGAAAGGTAGACAC-3  and 5 -CAGCAATGCCTGTCCGCATGTCAG-
CATAGC-3  for IRS-1; 5 -GAAGACAGTGGGTACATGCGAATG-3  and 5 -
CCTCATGGAGGAAGGCACTGCTG-3  for IRS-2; 5 -CATGTAGGCCAT-
GAGGTCCACCAC-3  and 5 -TGAAGGTCGGTGTGAACGGATTTGGC-3 
for G3PDH; 5 -GCACCGCCGAGATGGACTGCTGAA-3  and 5 -GGCG-
GAAAGAGGATGGAGGTGACG-3  for Runx2; 5 -CCTGCTGCCTCCCTG-
TAA-3  and 5 -CTTCACCGCTCACATTTCTC-3  for Lrp5; 5 -ACTGAGG-
GACCAGATGGACTCCAG-3  and 5 -GCCAGTGATCATTGTAATATACA-3 
for Id-1; 5 -CTGGGATGGACAAGGAGAGT-3  and 5 -AAGGCTGAGAG-
GCTATGGTG-3  for type I collagen; 5 -GCCCTCTCCAAGACATATA-3  and
5 -CCATGATCACGTCGATATCC-3  for ALP; 5 -AGTCGACATGAGATTG-
GCAGTGATTTGC-3  and 5 -ACTCGAGGCCTCTTCTTTAGTTGACCTC-3 
for osteopontin; 5 -TCGTTTCTTTCTGCTGGTCA-3  and 5 -CTTATTGC-
CCTCCTGCTTGG-3  for osteocalcin; 5 -GCATCGCTCTGTTCCTGTA-3 
and 5 -GTGCTCCCTCCTTTCATCA-3  for RANKL; 5 -TCCTGGCACCTAC-
CTAAAACAGCA-3  and 5 -CTACACTCTCGGCATTCACTTTGG-3  for os-
teoprotegerin; and 5 -CATTCAGCTATCCTGGCCACCTTC-3  and 5 -CATC-
CACATGGTTGGGAAGTTCTG-3  for MMP-13. Up to 25 cycles of am-
plification were performed with a PerkinElmer PCR thermal cycler (PE-2400)
at 94 C for 30 s, at 52–60 C for 60 s, and at 72 C for 90 s.
Statistical analysis
Means of groups were compared by ANOVA and significance of differ-
ences was determined by post-hoc testing using Bonferroni’s method.
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